Shilpa Medicare wins CDSCO approval for OERIS launch
In short
Shilpa Medicare has received final approval to market OERIS in India. The Subject Expert Committee under CDSCO cleared the drug, which is called Ondansetron Extended-Release Injection, 100 mg/mL.
This matters because the company can now move toward launch in India. The reporting does not say when sales will start or what the product will cost.
What the reporting says
Shilpa Medicare secured final marketing authorization approval for OERIS from the Subject Expert Committee under CDSCO, according to the reporting. OERIS is identified as Ondansetron Extended-Release Injection, 100 mg/mL. The immediate consequence is regulatory clearance for launch in India, while the reporting does not state a launch date, pricing, or commercial terms.
Why it matters
Shilpa Medicare announced that the Subject Expert Committee under CDSCO issued final approval for marketing authorization of OERIS, identified as Ondansetron Extended-Release Injection, 100 mg/mL. The decision gives the company regulatory clearance to launch in India. The reporting does not state the launch timing, pricing, or expected market size.